Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

1.4K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.4K
Essential Minerals for Bone Health01:31

Essential Minerals for Bone Health

5.7K
The minerals contained in all of the food we consume are essential for our organ systems. However, certain essential minerals, such as calcium, phosphorus, magnesium, manganese, and fluoride, largely affect bone health.
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
5.7K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.1K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.5K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver Fibrosis Estimated Using Noninvasive Blood Biochemical Indices Is Correlated with Visit-to-Visit Glycated Hemoglobin A1c Variability in Individuals with Type 2 Diabetes.

Biomedicines·2026
Same author

Protocolized Weaning From Mechanical Ventilation in the PICU: A Systematic Review and Meta-Analysis.

Pediatric pulmonology·2026
Same author

Editorial comment.

Journal of bone and mineral metabolism·2026
Same author

Editorial comment.

Journal of bone and mineral metabolism·2025
Same author

Red blood cell distribution width is associated with renal tubular injury in individuals with type 2 diabetes.

Journal of diabetes investigation·2025
Same author

Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice.

Antioxidants (Basel, Switzerland)·2025

Related Experiment Video

Updated: Dec 21, 2025

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

28.2K

Minodronate.

Toshio Matsumoto1, Itsuro Endo2

  • 1Fujii Memorial Institute of Medical Sciences, Tokushima University, Japan.

Bone
|May 19, 2020
PubMed
Summary
This summary is machine-generated.

Minodronate, a potent bisphosphonate, effectively inhibits bone resorption by targeting farnesyl pyrophosphate synthase. This review covers its mechanism, properties, and efficacy in treating osteoporosis, including bone quality, density, and fracture prevention.

Keywords:
Bone mineral densityBone qualityFarnesyl pyrophosphate synthaseFracture preventionHeterocyclic nitrogen-containing bisphosphonateHydroxyapatite affinity

More Related Videos

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.6K
Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis
08:13

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

10.9K

Related Experiment Videos

Last Updated: Dec 21, 2025

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

28.2K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.6K
Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis
08:13

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

10.9K

Area of Science:

  • Pharmacology
  • Biochemistry
  • Orthopedics

Background:

  • Minodronate is a nitrogen-containing bisphosphonate developed in Japan.
  • It exhibits high potency in inhibiting bone resorption.
  • Its mechanism involves targeting farnesyl pyrophosphate synthase.

Purpose of the Study:

  • To review the mechanism of action of minodronate.
  • To summarize its physico-chemical properties and effects on bone.
  • To evaluate its efficacy and safety in osteoporosis treatment.

Main Methods:

  • Literature review of studies on minodronate.
  • Analysis of its effects on bone resorption, bone quality, bone mineral density, and fracture prevention in animal models and patients.
  • Assessment of its interaction with hydroxyapatite and its in vivo anti-resorptive activity.

Main Results:

  • Minodronate potently inhibits farnesyl pyrophosphate synthase.
  • It shows lower affinity for hydroxyapatite, leading to minimal bone deposition but strong in vivo anti-resorptive activity.
  • Studies indicate positive effects on bone turnover, bone mineral density, and fracture prevention in osteoporosis.

Conclusions:

  • Minodronate demonstrates significant anti-resorptive activity with a favorable profile for osteoporosis treatment.
  • Its unique properties contribute to its efficacy despite low bone matrix affinity.
  • The review provides a comprehensive overview of minodronate's therapeutic potential in managing osteoporosis.